Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo

類似資料

• MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
  著者:: Ninomiya, Kiichiro, 等
  出版事項: (2018)
• Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
  著者:: Nishii, Kazuya, 等
  出版事項: (2021)
• Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
  著者:: Ichihara, Eiki, 等
  出版事項: (2018)
• Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model
  著者:: Hayakawa, Hiromi, 等
  出版事項: (2013)
• Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
  著者:: Go Makimoto, 等
  出版事項: (2022-05-01)